Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$5.20 USD
-0.15 (-2.80%)
Updated Apr 26, 2024 03:09 PM ET
After-Market: $5.11 -0.09 (-1.73%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
APRE 5.20 -0.15(-2.80%)
Will APRE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APRE
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
Other News for APRE
Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating
Optimistic Outlook for Aprea Therapeutics’ Oncology Pipeline: A Comprehensive Buy Rating Analysis
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Aprea Therapeutics files to sell 4.39M shares of common stock for holders